Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Citius Oncology, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CTOR
Nasdaq
2830
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Citius Oncology, Inc.
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
- Feb 6th, 2025 1:55 pm
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
- Jan 7th, 2025 1:08 pm
Citius Oncology to explore strategic alternatives
- Jan 7th, 2025 12:57 pm
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
- Jan 6th, 2025 12:50 pm
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
- Dec 31st, 2024 12:10 pm
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
- Dec 27th, 2024 10:00 pm
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
- Dec 27th, 2024 10:00 pm
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability
- Nov 28th, 2024 11:04 am
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 5th, 2024 8:30 pm
Scroll